Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
Open accessThe DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. As these intracellular second messengers control many cellular homeostatic processes, dysregulation of their signals and signaling pathways initiate or modulate pathophysiological pathways related to various disease states, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication, chronic obstructive pulmonary disease, and psoriasis. Alterations in expression of PDEs and PDE‐gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. PDEs also play important role in formation and function of multimolecular signaling/regulatory complexes, called signalosomes. At specific intracellular locations, individual PDEs, together with pathway‐specific signaling molecules, regulators, and effectors, are incorporated into specific signalosomes, where they facilitate and regulate compartmentalization of cyclic nucleotide signaling pathways and specific cellular functions. Currently, only a limited number of PDE inhibitors (PDE3, PDE4, PDE5 inhibitors) are used in clinical practice. Future paths to novel drug discovery include the crystal structure‐based design approach, which has resulted in generation of more effective family‐selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lynch, M. J., Baillie, G. S., Mohamed, A., Li, X., Maisonneuve, C., Klussmann, E., van Heeke, G., & Houslay, M. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414316200 · Cited by 206 · cited 22×
“…AC Cardiac I(Ks) potassium channel and arrhythmia (Terrenoire et al, 2009) AKAP79 PDE4D, b-arrestin, b2AR, ERK, PKA b2AR activation of ERK (Lynch et al, 2005) AKAP95, AKAP149, MTG PDE4A, PDE7A, PKA-RII Activation of T-cells (Asirvatham et al, 2004) mAKAP PDE4D, PKA, RyR2 Myocardial…”
InfluentialRetractedOsteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Maintenance of normal bone mass depends on the balance between osteoblast bone formation and osteoclast bone destruction (Duong and Rodan, 2001; Boyle et al, 2003).”
BackgroundCardiac excitation–contraction coupling
Bers, D. M. (2002) · Nature · doi:10.1038/415198a · Cited by 4,744 · cited 1×
“Thus, as components of different AKAP-based signalosomes, PDE4B, PDE4D, and PDE3A regulate different phases of the calcium-mediated excitation–contraction coupling cycle and offer Oral Diseases 9 protection against arrhythmias (Bers, 2002).”
BackgroundEffect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225 · cited 1×
“Although PDE3 inhibitors were developed to improve hemodynamic responses in patients with heart failure, in clinical trials, chronic administration of the PDE3 inhibitor milrinone increased mortality, most likely due to arrhythmias and cardiac arrest (Packer et al, 1991).”
BackgroundEpac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969 · cited 1×
“…sites in addition to their catalytic sites (Bender and Beavo, 2006; Manganiello et al, 2007; Tsai and Kass, 2009; Francis et al, 2011). cAMP binding directly activates Epac proteins, resulting in activation of Rap1 (small GTPase) and diverse Rap1signaling pathways (de Rooij et al, 1998; Bos, 2006).”
BackgroundCyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781 · cited 23×
“mediate cyclic nucleotide actions, for example, Epac 1 and Epac 2 (cAMP-activated guanine-nucleotide-exchange proteins), cyclic-nucleotide-gated (CNG) ion channels, and several PDEs (especially PDEs 2, 5, 6) that contain allosteric cyclic-nucleotide-binding sites in addition to their catalytic sites (Bender and Beavo,…”
BackgroundInfluentialResveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Self-citationConti, M., & Beavo, J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.150444 · Cited by 1,183 · cited 2×
“…include two domains: NHR1 (amino acids 1–300), which contains a large hydrophobic domain with five to six predicted transmembrane helices, and NHR2 (aa 300–500), with a smaller hydrophobic region of ~50 aa (Taira et al, 1993; Degerman et al, 1997; Hambleton et al, 2005; Conti and Beavo, 2007).”
BackgroundGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
Francis, S. H., Busch, J. L., & Corbin, J. D. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002907 · Cited by 1,028 · cited 1×
“PDE1 activity is determined by intracellular Ca2+ levels (Francis et al, 2010).”
Background
Cited by
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Metadata
- Authors
- Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V
- Venue
- Oral Diseases
- Publisher
- Wiley
- Published
- 2014-09-12
- Volume
- 21
- Issue
- 1
- Pages
- e25-50
- ISSN
- 1354-523X (ISSN-L)
- 1601-0825
- OpenAlex
- W2049374415
- Cited by
- 184
- References
- 261
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.